Drugs / PD-1 blocking antibody
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04268537 | Feb → Apr 2020 | COVID-19 | Southeast University, China | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PD-1 blocking antibody | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04268537 ↗ |
| Action | Inhibit | “Monoclonal antibody blocking the activity of PD-1” NCT04268537 ↗ |
| Modality | Monoclonal antibody | “Monoclonal antibody blocking the activity of PD-1 can successfully reduce tumor load” NCT04268537 ↗ |
| Route | Intravenous | “PD-1 blocking antibody 200mg iv, one time” NCT04268537 ↗ |